Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

1681results about How to "Inhibition is effective" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Liquid material vaporization apparatus for semiconductor processing apparatus

ActiveUS20080173240A1Reduce the temperatureLow thermal conductivitySteam generation heating methodsSpray nozzlesVaporizationEngineering

A liquid material vaporization apparatus for a semiconductor processing apparatus includes: a vaporization tank; an inner partition wall disposed in the tank for dividing the interior of the tank into a charging compartment and a vaporization compartment which are liquid-communicatable with each other over an upper edge of the inner partition wall. A liquid material charged in the charging compartment overflows over the upper edge of the inner partition wall toward the vaporization compartment to store and vaporize the liquid material in the vaporization compartment.

Liquid material vaporization apparatus for semiconductor processing apparatus

View all

Owner:ASM JAPAN

Liquid material vaporization apparatus for semiconductor processing apparatus

ActiveUS7833353B2Reduce the temperatureInhibition is effectiveSteam generation heating methodsSpray nozzlesVaporizationEngineering

View all

Owner:ASM JAPAN

Method of depositing silicon oxide film by plasma enhanced atomic layer deposition at low temperature

ActiveUS8197915B2Increase deposition rateInhibition is effectiveSemiconductor/solid-state device manufacturingPhotosensitive material processingResistDeposition temperature

A method of depositing a silicon oxide film on a resist pattern or etched lines formed on a substrate by plasma enhanced atomic layer deposition (PEALD) includes: providing a substrate on which a resist pattern or etched lines are formed in a PEALD reactor; controlling a temperature of a susceptor on which the substrate is placed at less than 50° C. as a deposition temperature; introducing a silicon-containing precursor and an oxygen-supplying reactant to the PEALD reactor and applying RF power therein in a cycle, while the deposition temperature is controlled substantially or nearly at a constant temperature of less than 50° C., thereby depositing a silicon oxide atomic layer on the resist pattern or etched lines; and repeating the cycle multiple times substantially or nearly at the constant temperature to deposit a silicon oxide atomic film on the resist pattern or etched lines.

Method of depositing silicon oxide film by plasma enhanced atomic layer deposition at low temperature

View all

Owner:ASM JAPAN

Method of Depositing Silicon Oxide Film by Plasma Enhanced Atomic Layer Deposition at Low Temperature

ActiveUS20100255218A1Increase deposition rateInhibition is effectiveLiquid surface applicatorsSemiconductor/solid-state device manufacturingResistDeposition temperature

View all

Owner:ASM JAPAN

Method for forming oxide film by plasma-assisted processing

ActiveUS9284642B2Inhibition is effectiveHigh affinitySemiconductor/solid-state device manufacturingChemical vapor deposition coatingOxygenAnalytical chemistry

A method for forming an oxide film by plasma-assisted processing includes: (i) supplying a precursor reactive to none of oxygen, CxOy, and NxOy (x and y are integers) without a plasma to a reaction space wherein a substrate is placed; (ii) exposing the precursor to a plasma of CxOy and / or NxOy in the reaction space; and (iii) forming an oxide film on the substrate using the precursor and the plasma.

Method for forming oxide film by plasma-assisted processing

View all

Owner:ASM IP HLDG BV

Method for Forming Oxide Film by Plasma-Assisted Processing

ActiveUS20150079311A1Effectively inhibitIncrease in RF powerSemiconductor/solid-state device manufacturingChemical vapor deposition coatingOxideAnalytical chemistry

A method for forming an oxide film by plasma-assisted processing includes: (i) supplying a precursor reactive to none of oxygen, C_xO_y, and N_xO_y(x and y are integers) without a plasma to a reaction space wherein a substrate is placed; (ii) exposing the precursor to a plasma of C_xO_yand/or N_xO_yin the reaction space; and (iii) forming an oxide film on the substrate using the precursor and the plasma.

View all

Owner:ASM IP HLDG BV

Method and system for detecting intrusion into and misuse of a data processing system

InactiveUS6839850B1Lower the volumeEasy activityMemory loss protectionUnauthorized memory use protectionData miningHandling system

Disclosed is a Security Indications and Warning (SI&W) Engine usable in conjunction with an audit agent. The audit agent forwards normalized audits to the SI&W Engine. The SI&W Engine groups the normalized audits into related groupings. Gauges are used to count the number of occurrences of audited events. A statistical engine provides statistical representations of the number of events per user, per session and per node. A predetermined number of criteria are defined a particular gauge or gauge pair. There may be many criteria for a particular network. When a predetermined number of criteria within a criteria set are triggered, an indicator is triggered. More complex indicators can use combinations of lower level indicators to provide further indications of potential security threads. Thus, a hierarchical system of gauges, criteria and indicators is used to measure boundary violations and breaches of different barriers. Advantageously, because there are no predefined scenarios or profiles that must be performed by a potential misuser or intruder, the SI&W Engine of the present invention is capable of indicating that a potential security threat exists in near-real time.

Method and system for detecting intrusion into and misuse of a data processing system

View all

Owner:NORTHROP GRUMMAN SYST CORP +1

Compositions and methods of delivery of pharmacological agents

InactiveUS20050004002A1Reducing one or more side effectsInhibiting oxidation in the pharmaceutical compositionAntibacterial agentsOrganic active ingredientsSide effectPharmaceutical formulation

The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and / or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.

Owner:ABRAXIS BIOSCI LLC

Semiconductor Device and Method for Manufacturing Semiconductor Device

InactiveUS20090243065A1Improve joint reliabilityLower elastic modulusSemiconductor/solid-state device detailsSolid-state devicesSurface mountingSemiconductor chip

A semiconductor device (100) comprises a first resin substrate (101) on which a first semiconductor chip (125) is mounted a surface thereof; a second resin substrate (111) on which a second semiconductor chip (131) is mounted on a surface thereof; and a resin base material (109), joined to a front surface of the first resin substrate (101) and to a back surface of the second resin substrate (111), so that these surfaces are electrically connected. The resin base material (109) is disposed in a circumference of the first resin substrate (101) in the surface of the first resin substrate (101). Further, the first semiconductor chip (125) is disposed in a space section provided among the first resin substrate (101), the second resin substrate (111) and the resin base material (109) in the surface of the first resin substrate (101).

Semiconductor Device and Method for Manufacturing Semiconductor Device

View all

Owner:SUMITOMO BAKELITE CO LTD

Aneurysm treatment device and method of use

InactiveUS7572288B2Impaired blood flowEasy to manufactureStentsElectrotherapyMedicineAneurysm treatment

The present invention is directed to aneurysm treatment devices which are capable of being delivered to the situs of a vascular aneurysm through a catheter. The treatment devices comprise, in general, an expandable stent having fenestrations and a reactive material selectively applied to not all of the fenestrations. The reactive material has a non-reacted state and a reacted state and the reactive material in the reacted state is capable of increasing the resistance to blood flow through said fenestrations.

Aneurysm treatment device and method of use

View all

Owner:MICROVENTION INC

Thermoplastic dicyclopentadiene-base open-ring polymers, hydrogenated derivatives thereof, and processes for the preparation of both

InactiveUS6511756B1Improve efficiencyGood moldabilityPlastic/resin/waxes insulatorsSynthetic resin layered productsThermoplasticDouble bond

A thermoplastic dicyclopentadiene ring-opening polymer obtained by ring-opening polymerization of a monomer component containing a dicyclopentadiene monomer, characterized in that polycyclic rings which are repeating units of the polymer are bonded in cis-position relative to the carbon-carbon double bond of the main chain of the polymer in 50 mol % or more of the repeating units based on the total repeating units and the content of a low-molecular weight component of 2,000 or less in molecular weight is 10% by weight or less based on the total polymer components, and a hydrogenation product obtained by hydrogenating the carbon-carbon unsaturated bond of the thermoplastic dicyclopentadiene ring-opening polymer.

Thermoplastic dicyclopentadiene-base open-ring polymers, hydrogenated derivatives thereof, and processes for the preparation of both

View all

Owner:ZEON CORP

Deposition mask, method for manufacturing display unit using it, and display unit

ActiveUS20050001546A1Reduced film thickness distributionWiring resistance differenceDischarge tube luminescnet screensElectroluminescent light sourcesOrganic light emitting deviceOrganic layer

A deposition mask and a display unit and method of manufacturing same are provided. A red continuous organic layer, a green continuous organic layer, and a blue continuous organic layer are provided over two or more lines of a matrix configuration of organic light emitting devices in common. A film thickness distribution in the extensional direction of the red, green and blue continuous organic layer is dissolved, and an aperture ratio can be improved by just that much.

Deposition mask, method for manufacturing display unit using it, and display unit

View all

Owner:SONY CORP

Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof

InactiveUS6268363B1Inhibition is effectiveInhibitory activityOrganic chemistryUrinary disorderFarnesyl Protein TransferaseBULK ACTIVE INGREDIENT

The present invention relates to a novel imidazole derivative represented by formula (1) which shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts or isomers thereof, in which A, n1 and Y are defined in the specification; to a process for preparation of the compound of formula (1); to intermediates which are used in the preparation of the compound of formula (1); and to a pharmaceutical composition comprising the compound of formula (1) as an active ingredient.

Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof

View all

Owner:LG CHEM LTD

Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus

InactiveUS20060257980A1Inhibit functioningEffective treatmentDigestive systemAntiviralsIsoquinolineCombinatorial chemistry

Macrocyclic isoquinoline peptides are disclosed having the general formula: A compound of formula I: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus

View all

Owner:BRISTOL MYERS SQUIBB CO

Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof

InactiveUS6436960B1Inhibition is effectiveInhibitory activityBiocideOrganic chemistryFarnesyl TransferaseFarnesyl Transferase Inhibitor

The present invention relates to a novel piperidine derivative represented by formula (1) which shows an inhibitory activity against farnesyl transferase or pharmaceutically acceptable salts thereof, in which A, E and G are defined in the specification; to a process for preparation of the compound of formula (1); to an intermediate which is used in the preparation of the compound of formula (1); and to a pharmaceutical composition comprising the compound of formula (1) as an active ingredient.

Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof

View all

Owner:LG CHEM LTD

Libraries of peptide conjugates and methods for making them

InactiveUS20110172126A1Reduce hydrolysisReduce degradationPeptide librariesNervous disorderNitrogenInducer

The invention relates to peptide conjugates including at least one turn inducer wherein the turn inducer comprises a 5-7 membered saturated or unsaturated nitrogen containing heterocyclic ring and methods of making the peptides. Libraries of these peptides, methods of making the libraries are also described and methods of screening the libraries for therapeutic activity are also described.

Libraries of peptide conjugates and methods for making them

View all

Owner:XENOME

Aneurysm Treatment Device And Method Of Use

InactiveUS20090287297A1Effective occlusionInhibition is effectiveStentsOcculdersAneurysm treatmentReactive material

The present invention is directed to aneurysm treatment devices which are capable of being delivered to the situs of a vascular aneurysm through a catheter. The treatment devices comprise, in general, a body member formed by at least one support member and a reactive material selectively applied to the at least one support member. The body member provide support mechanical support to a weakened or otherwise incompetent blood vessel. The reactive material is capable of restricting or occluding blood flow to the aneurysm, without substantially affecting blood flow through the blood vessel.

View all

Owner:MICROVENTION INC

Hepatitis C virus inhibitors

ActiveUS7132504B2Inhibit functioningEffective treatmentBiocidePeptide/protein ingredientsBiochemistryVirus

Compounds are disclosed having the general formula:wherein R1, R2, R3, R4, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

View all

Owner:BRISTOL MYERS SQUIBB CO

Novel pyrimidine compounds, process for their preparation and compositions containing them

InactiveUS20060084645A1Inhibit inflammationInhibition is effectiveBiocideOrganic chemistryDyslipidemiaNephrosis

The present invention provides new heterocyclic compounds, particularly substituted pyrimidines, methods and compositions for making and using these heterocyclic compounds, and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan.

Novel pyrimidine compounds, process for their preparation and compositions containing them

View all

Owner:DR REDDYS LAB LTD

Nonaqueous electrolyte secondary battery

InactiveUS20060078787A1Excellent output characteristicImprove output characteristicsPrimary cell maintainance/servicingCell temperature controlInternal pressureEngineering

The invention provides a nonaqueous electrolyte secondary battery excellent in output characteristic such as large current discharge or pulse discharge in ordinary use, high in safety by preventing destruction due to suppression of current in an abnormality such as external short-circuiting, and further large in capacity. The nonaqueous electrolyte secondary battery comprises an external can opened at one end thereof, an electrode assembly contained in the external can, and comprising a negative electrode, a separator and a positive electrode, a nonaqueous electrolyte contained in the external can, and a sealing lid group tightly sealed at the opening of the external can by way of an insulating member, wherein the sealing lid group includes an intact plate-like PTC element having a fragile portion to be easily broken due to elevation of internal pressure by gas generation.